{"transactions":[{"id":693129,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2026-08-07T21:24:36.000Z","date":"2026-08-07","kind":"gift","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":662701,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001507678-26-000006","document":"wk-form4_1786137872.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000006/wk-form4_1786137872.xml","form_type":"4"}},{"id":693128,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-08-07T21:24:36.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":65216,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1307820,"source":{"system":"sec-edgar","filing":"0001507678-26-000006","document":"wk-form4_1786137872.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000006/wk-form4_1786137872.xml","form_type":"4"}},{"id":758840,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-05-29T20:04:17.000Z","date":"2026-05-28","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":135000,"derivative":{"exercise_price":1.81,"expiration_date":"2036-05-28","underlying":"Class A Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001193125-26-248221","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526248221/ownership.xml","form_type":"4"}},{"id":786927,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-05-08T21:17:16.000Z","date":"2026-05-06","kind":"grant","planned":false,"acquired":true,"shares":143821,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1242604,"source":{"system":"sec-edgar","filing":"0001507678-26-000004","document":"wk-form4_1778275033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000004/wk-form4_1778275033.xml","form_type":"4"}},{"id":905320,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2026-02-13T21:03:47.000Z","date":"2026-02-11","kind":"grant","planned":false,"acquired":true,"shares":157828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":1098783,"source":{"system":"sec-edgar","filing":"0001507678-26-000002","document":"wk-form4_1771016624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767826000002/wk-form4_1771016624.xml","form_type":"4"}},{"id":1004926,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2025-11-07T21:19:27.000Z","date":"2025-11-05","kind":"grant","planned":false,"acquired":true,"shares":36559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":940955,"source":{"system":"sec-edgar","filing":"0001507678-25-000010","document":"wk-form4_1762550365.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000150767825000010/wk-form4_1762550365.xml","form_type":"4"}},{"id":1071419,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2025-08-08T21:00:00.000Z","date":"2025-08-08","kind":"gift","planned":false,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":692701,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001802768-25-000105","document":"wk-form4_1754686796.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000105/wk-form4_1754686796.xml","form_type":"4"}},{"id":1071418,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2025-08-08T21:00:00.000Z","date":"2025-08-06","kind":"grant","planned":false,"acquired":true,"shares":21901,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":904396,"source":{"system":"sec-edgar","filing":"0001802768-25-000105","document":"wk-form4_1754686796.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000105/wk-form4_1754686796.xml","form_type":"4"}},{"id":1121607,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2025-06-05T16:15:27.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":false,"shares":3823996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":84283430,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":3823996},"source":{"system":"sec-edgar","filing":"0000950170-25-082342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025082342/ownership.xml","form_type":"4"}},{"id":1121606,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2025-06-05T16:15:27.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":false,"shares":3823996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":84283430,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":3823996},"source":{"system":"sec-edgar","filing":"0000950170-25-082342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025082342/ownership.xml","form_type":"4"}},{"id":1121605,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-06-05T16:15:27.000Z","date":"2025-06-03","kind":"other","planned":false,"acquired":false,"shares":3823996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Prior to June 3, 2025 (the \"Transaction Date\"), Tolerantia held 88,107,426 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the \"Paired Interests\"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 3,946,889 of which were held by other investors which are unaffiliated with Mr. Legorreta (the \"Unaffiliated Investors\"). On the Transaction Date, Tolerantia exchanged 3,823,996 of the 3,946,889 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 3,823,996 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":22617909,"source":{"system":"sec-edgar","filing":"0000950170-25-082342","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025082342/ownership.xml","form_type":"4"}},{"id":1121604,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-06-05T16:15:27.000Z","date":"2025-06-03","kind":"exercise","planned":false,"acquired":true,"shares":3823996,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":26441905,"source":{"system":"sec-edgar","filing":"0000950170-25-082342","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025082342/ownership.xml","form_type":"4"}},{"id":1127797,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-02T20:15:29.000Z","date":"2025-05-29","kind":"grant","planned":false,"acquired":true,"shares":125862,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":125862,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-29","underlying":"Class A Ordinary Shares","underlying_shares":125862},"source":{"system":"sec-edgar","filing":"0000950170-25-080277","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017025080277/ownership.xml","form_type":"4"}},{"id":1140525,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Option (Right to Buy)","published_at":"2025-05-20T20:49:25.000Z","date":"2025-05-16","kind":"other","planned":false,"acquired":true,"shares":857138,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By PL RPH Holdings, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents the Reporting Person's right to acquire certain Class E Shares held by other employees of the Issuer and its subsidiaries in the event such Class E Shares are forfeited by such employee."}],"balance_after":857138,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":857138},"source":{"system":"sec-edgar","filing":"0001802768-25-000063","document":"wk-form4_1747774159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000063/wk-form4_1747774159.xml","form_type":"4"}},{"id":1140524,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class E Ordinary Shares","published_at":"2025-05-20T20:49:25.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":13356742,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By PL RPH Holdings, LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares (\"Class E Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the \"Purchase Agreement\") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares (\"Class E Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as may be amended from time to time, the \"Purchase Agreement\") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Each Class E share will vest in installments over a 5-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH (\"Class B Shares\") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis, and there is no expiration date for such conversion."}],"balance_after":13356742,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":13356742},"source":{"system":"sec-edgar","filing":"0001802768-25-000063","document":"wk-form4_1747774159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000063/wk-form4_1747774159.xml","form_type":"4"}},{"id":1140523,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2025-05-20T20:49:25.000Z","date":"2025-05-16","kind":"other","planned":false,"acquired":true,"shares":530348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the transfer to the Reporting Person by the RP Management Equity Incentive Plan Trust of Class A Ordinary Shares for no consideration."}],"balance_after":882495,"source":{"system":"sec-edgar","filing":"0001802768-25-000063","document":"wk-form4_1747774159.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000063/wk-form4_1747774159.xml","form_type":"4"}},{"id":1149289,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class B Ordinary Shares","published_at":"2025-05-14T21:02:26.000Z","date":"2025-05-12","kind":"gift","planned":false,"acquired":true,"shares":867180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an exempt gift for no consideration of Class B ordinary shares (\"Class B Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the exempt transfer pursuant to Rule 16a-13 of Class B Shares from the reporting person and the GST-Exempt Legorreta 2020 Family Trust to PL RPH AIV, LLC, which is solely beneficially owned by the reporting person. The Class B Shares transferred by the reporting person and the GST-Exempt Legorreta 2020 Family Trust were originally received in exempt pro rata distributions pursuant to Rule 16a-9(a) and the gift transaction reported in this filing."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":867180},"source":{"system":"sec-edgar","filing":"0001802768-25-000043","document":"wk-form4_1747256539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000043/wk-form4_1747256539.xml","form_type":"4"}},{"id":1149288,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class B Ordinary Shares","published_at":"2025-05-14T21:02:26.000Z","date":"2025-05-12","kind":"gift","planned":false,"acquired":false,"shares":867180,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an exempt gift for no consideration of Class B ordinary shares (\"Class B Shares\") of Royalty Pharma Holdings Ltd (\"RPH\") from the reporting person's spouse to the reporting person. The Class B Shares held by the reporting person's spouse were originally received in an exempt pro rata distribution pursuant to Rule 16a-9(a)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each Class B Share may be converted at any time into an equivalent number of  Class A ordinary shares of the Issuer on a one-for-one basis (at which time, a corresponding number of Class B ordinary shares will also be forfeited and redesignated on a one-for-one basis), and there is no expiration date for such conversion."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":867180},"source":{"system":"sec-edgar","filing":"0001802768-25-000043","document":"wk-form4_1747256539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000043/wk-form4_1747256539.xml","form_type":"4"}},{"id":1153819,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2025-05-09T21:18:28.000Z","date":"2025-05-08","kind":"grant","planned":false,"acquired":true,"shares":288352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards."}],"balance_after":352147,"source":{"system":"sec-edgar","filing":"0001802768-25-000039","document":"wk-form4_1746825503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000180276825000039/wk-form4_1746825503.xml","form_type":"4"}},{"id":1280457,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2025-02-06T17:02:57.000Z","date":"2025-02-04","kind":"exercise","planned":false,"acquired":false,"shares":532535,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":88107426,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":532535},"source":{"system":"sec-edgar","filing":"0000950170-25-015495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025015495/ownership.xml","form_type":"4"}},{"id":1280456,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2025-02-06T17:02:57.000Z","date":"2025-02-04","kind":"exercise","planned":false,"acquired":false,"shares":532535,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":88107426,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":532535},"source":{"system":"sec-edgar","filing":"0000950170-25-015495","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025015495/ownership.xml","form_type":"4"}},{"id":1280455,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-02-06T17:02:57.000Z","date":"2025-02-04","kind":"other","planned":false,"acquired":false,"shares":532535,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Prior to February 4, 2025 (the \"Transaction Date\"), Tolerantia held 88,639,961 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the \"Paired Interests\"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 4,479,424 of which were held by other investors which are unaffiliated with Mr. Legorreta (the \"Unaffiliated Investors\"). On the Transaction Date, Tolerantia exchanged 532,535 of the 4,479,424 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 532,535 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":22617909,"source":{"system":"sec-edgar","filing":"0000950170-25-015495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025015495/ownership.xml","form_type":"4"}},{"id":1280454,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2025-02-06T17:02:57.000Z","date":"2025-02-04","kind":"exercise","planned":false,"acquired":true,"shares":532535,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":23150444,"source":{"system":"sec-edgar","filing":"0000950170-25-015495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017025015495/ownership.xml","form_type":"4"}},{"id":1479407,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-06-14T16:05:17.000Z","date":"2024-06-13","kind":"purchase","planned":false,"acquired":true,"shares":22617909,"price":2.42,"value":54735339.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by or for the benefit of Tolerantia, LLC, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia, LLC. Mr. Legorreta disclaims beneficial ownership of the equity interests held by or for the benefit of Tolerantia, LLC except to the extent of his indirect pecuniary interest therein."}],"balance_after":22617909,"source":{"system":"sec-edgar","filing":"0000950170-24-073633","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017024073633/ownership.xml","form_type":"4"}},{"id":1495285,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-03T20:33:37.000Z","date":"2024-05-30","kind":"grant","planned":false,"acquired":true,"shares":62558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":62558,"derivative":{"exercise_price":4.2,"expiration_date":"2034-05-30","underlying":"Class A Ordinary Shares","underlying_shares":62558},"source":{"system":"sec-edgar","filing":"0000950170-24-068045","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000095017024068045/ownership.xml","form_type":"4"}},{"id":1657082,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2024-02-06T16:05:13.000Z","date":"2024-02-05","kind":"exercise","planned":false,"acquired":false,"shares":748952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":88639961,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":748952},"source":{"system":"sec-edgar","filing":"0000950170-24-011711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017024011711/ownership.xml","form_type":"4"}},{"id":1657081,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2024-02-06T16:05:13.000Z","date":"2024-02-05","kind":"exercise","planned":false,"acquired":false,"shares":748952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":88639961,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":748952},"source":{"system":"sec-edgar","filing":"0000950170-24-011711","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017024011711/ownership.xml","form_type":"4"}},{"id":1657080,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-02-06T16:05:13.000Z","date":"2024-02-05","kind":"other","planned":false,"acquired":false,"shares":748952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Prior to February 5, 2024 (the \"Transaction Date\"), Tolerantia held 89,388,913 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the \"Paired Interests\"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 5,228,376 of which were held by other investors which are unaffiliated with Mr. Legorreta (the \"Unaffiliated Investors\"). On the Transaction Date, Tolerantia exchanged 748,952 of the 5,228,376 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 748,952 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-011711","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017024011711/ownership.xml","form_type":"4"}},{"id":1657079,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2024-02-06T16:05:13.000Z","date":"2024-02-05","kind":"exercise","planned":false,"acquired":true,"shares":748952,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":748952,"source":{"system":"sec-edgar","filing":"0000950170-24-011711","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095017024011711/ownership.xml","form_type":"4"}},{"id":1739195,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-11-16T22:50:58.000Z","date":"2023-11-16","kind":"other","planned":false,"acquired":false,"shares":383000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the transfer by the Reporting Person of Class A ordinary shares for no consideration to RP Management Equity Incentive Plan Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the exempt transfer pursuant to Rule 16a-13 of Class A ordinary shares from the GST-Exempt Legorreta 2012 Family Trust."}],"balance_after":63795,"source":{"system":"sec-edgar","filing":"0000950103-23-016404","document":"dp202859_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323016404/dp202859_4-legorreta.xml","form_type":"4"}},{"id":1739194,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-11-16T22:50:58.000Z","date":"2022-12-30","kind":"gift","planned":false,"acquired":true,"shares":292190.49,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Tata MC 35 Ltd."},"balance_after":292190.49,"source":{"system":"sec-edgar","filing":"0000950103-23-016404","document":"dp202859_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323016404/dp202859_4-legorreta.xml","form_type":"4"}},{"id":1752545,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2023-11-01T17:27:27.000Z","date":"2023-10-30","kind":"exercise","planned":false,"acquired":false,"shares":5289055,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney LP. The Common Units do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":89388913,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":5289055},"source":{"system":"sec-edgar","filing":"0001209191-23-054044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000120919123054044/doc4.xml","form_type":"4"}},{"id":1752544,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2023-11-01T17:27:27.000Z","date":"2023-10-30","kind":"exercise","planned":false,"acquired":false,"shares":5289055,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The Class B Ordinary Shares and the Common Units in ProKidney LP (the \"Common Units\") are paired securities. At the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, each Class B Ordinary Share, together with a paired Common Unit, may be exchanged for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement by and between the Issuer (formerly known as Social Capital Suvretta Holdings Corp. III) and ProKidney LP, dated as of January 18, 2022 (the \"Business Combination Agreement\"), in exchange for historical interests held by the reporting person in ProKidney LP. The Class B Ordinary Shares do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":89388913,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":5289055},"source":{"system":"sec-edgar","filing":"0001209191-23-054044","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000120919123054044/doc4.xml","form_type":"4"}},{"id":1752543,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-11-01T17:27:27.000Z","date":"2023-10-30","kind":"other","planned":false,"acquired":false,"shares":5289055,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Prior to October 30, 2023 (the \"Transaction Date\"), Tolerantia held 94,677,968 Common Units in ProKidney and an equal number of Class B Ordinary Shares (the \"Paired Interests\"), 84,160,537 of which were held by Nefro Health, an Irish partnership that is an affiliate controlled and majority-owned by Mr. Pablo Legorreta, and 10,517,431 of which were held by other investors which are unaffiliated with Mr. Legorreta (the \"Unaffiliated Investors\"). On the Transaction Date, Tolerantia exchanged 5,289,055 of the 10,517,431 Paired Interests attributable to the interests of the Unaffiliated Investors in Tolerantia for 5,289,055 Class A Ordinary Shares, which it subsequently distributed in-kind pro rata for no consideration to the Unaffiliated Investors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-054044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000120919123054044/doc4.xml","form_type":"4"}},{"id":1752542,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Ordinary Shares","published_at":"2023-11-01T17:27:27.000Z","date":"2023-10-30","kind":"exercise","planned":false,"acquired":true,"shares":5289055,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":5289055,"source":{"system":"sec-edgar","filing":"0001209191-23-054044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000120919123054044/doc4.xml","form_type":"4"}},{"id":1839818,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-07-03T13:16:19.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":48128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":48128,"derivative":{"exercise_price":10.56,"expiration_date":"2033-06-29","underlying":"Class A Ordinary Shares","underlying_shares":48128},"source":{"system":"sec-edgar","filing":"0001209191-23-040421","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850270/000120919123040421/doc4.xml","form_type":"4"}},{"id":1842758,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-06-28T20:01:12.000Z","date":"2023-06-28","kind":"purchase","planned":false,"acquired":true,"shares":130000,"price":29.5136,"value":3836768.0,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $29.40 to $29.60. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":600000,"source":{"system":"sec-edgar","filing":"0001209191-23-040024","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123040024/doc4.xml","form_type":"4"}},{"id":1857317,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-06-13T20:01:22.000Z","date":"2023-06-13","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":32.7756,"value":1474902.0,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.66 to $32.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":470000,"source":{"system":"sec-edgar","filing":"0001209191-23-036624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123036624/doc4.xml","form_type":"4"}},{"id":1857316,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-06-13T20:01:22.000Z","date":"2023-06-12","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":32.9988,"value":1484946.0,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.97 to $33.00. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":425000,"source":{"system":"sec-edgar","filing":"0001209191-23-036624","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123036624/doc4.xml","form_type":"4"}},{"id":1879835,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-05-24T22:45:59.000Z","date":"2023-05-24","kind":"purchase","planned":false,"acquired":true,"shares":150000,"price":32.2496,"value":4837440.0,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.20 to $32.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":380000,"source":{"system":"sec-edgar","filing":"0000950103-23-007785","document":"dp194284_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323007785/dp194284_4-legorreta.xml","form_type":"4"}},{"id":1889200,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-05-17T22:41:28.000Z","date":"2023-05-17","kind":"purchase","planned":false,"acquired":true,"shares":69612,"price":32.9411,"value":2293095.8532,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $32.70 to $33.28. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":230000,"source":{"system":"sec-edgar","filing":"0000950103-23-007427","document":"dp193902_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323007427/dp193902_4-legorreta.xml","form_type":"4"}},{"id":1889199,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A ordinary shares","published_at":"2023-05-17T22:41:28.000Z","date":"2023-05-16","kind":"purchase","planned":false,"acquired":true,"shares":160388,"price":33.5669,"value":5383727.9572,"ownership":{"direct":false,"nature":"By Legorreta 2023 SR Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares acquired by the reporting person in open market transactions as part of the reporting person's previously disclosed intention to purchase up to $50 million of the issuer's Class A ordinary shares, as announced in the issuer's press release on March 27, 2023 regarding the issuer's $1.0 billion share repurchase program."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The reported securities were purchased in multiple transactions at prices ranging from $33.48 to $33.76. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range."}],"balance_after":160388,"source":{"system":"sec-edgar","filing":"0000950103-23-007427","document":"dp193902_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323007427/dp193902_4-legorreta.xml","form_type":"4"}},{"id":1893626,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2023-05-16T01:34:37.000Z","date":"2023-05-12","kind":"gift","planned":false,"acquired":true,"shares":10269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an exempt gift for no consideration of ICAI Interests from the reporting person's spouse to the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests (\"RPI US LP Interests\") in RPI US Partners 2019, LP (\"RPI US LP\") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests (\"RPI US LP Interests\") in RPI US Partners 2019, LP (\"RPI US LP\") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the exempt change in the form of beneficial ownership without a change in the reporting person's pecuniary interest pursuant to Rule 16a-13 of certain ICAI Interests from being directly or indirectly owned by the reporting person through Legorreta Investments II LLC to being directly owned or indirectly owned through Legorreta Investments LLC and the reporting person's spouse."}],"balance_after":692701,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":10269},"source":{"system":"sec-edgar","filing":"0000950103-23-007321","document":"dp193834_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323007321/dp193834_4-legoretta.xml","form_type":"4"}},{"id":1893625,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2023-05-16T01:34:37.000Z","date":"2023-05-12","kind":"gift","planned":false,"acquired":false,"shares":10269,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects an exempt gift for no consideration of ICAI Interests from the reporting person's spouse to the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests (\"RPI US LP Interests\") in RPI US Partners 2019, LP (\"RPI US LP\") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These ICAI Interests represent a beneficial interest in an equivalent number of limited partnership interests (\"RPI US LP Interests\") in RPI US Partners 2019, LP (\"RPI US LP\") and may be exchanged into RPI US LP Interests on a one-for-one basis currently. The ICAI Interests do not have an expiration date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects the exempt change in the form of beneficial ownership without a change in the reporting person's pecuniary interest pursuant to Rule 16a-13 of certain ICAI Interests from being directly or indirectly owned by the reporting person through Legorreta Investments II LLC to being directly owned or indirectly owned through Legorreta Investments LLC and the reporting person's spouse."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":10269},"source":{"system":"sec-edgar","filing":"0000950103-23-007321","document":"dp193834_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010323007321/dp193834_4-legoretta.xml","form_type":"4"}},{"id":2022850,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2023-02-11T00:48:51.000Z","date":"2022-08-12","kind":"gift","acquired":false,"shares":150640,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"No limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with an exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":2700000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":1506400},"source":{"system":"sec-edgar","filing":"0001209191-23-008556","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000120919123008556/doc5.xml","form_type":"5"}},{"id":2183740,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124526,"kind":"person","name":"Royalty Pharma Investments 2019 ICAV","position":4,"cik":"0001909645","reported_name":"Royalty Pharma Investments 2019 ICAV","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-16T22:55:40.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the \"Funds\"), all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8994},"source":{"system":"sec-edgar","filing":"0000899243-22-028860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322028860/doc4.xml","form_type":"4"}},{"id":2183739,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124526,"kind":"person","name":"Royalty Pharma Investments 2019 ICAV","position":4,"cik":"0001909645","reported_name":"Royalty Pharma Investments 2019 ICAV","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-16T22:55:40.000Z","date":"2022-08-12","kind":"disposition_to_issuer","acquired":false,"shares":8060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Reflects disposition of restricted stock units (\"RSUs\") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each unvested RSU held by the Reporting Person automatically vested in full and was canceled and converted into the right to receive (i) an amount of cash equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Cash Consideration and (ii) one (1) CVR for each Share underlying such RSU, in each case, less applicable withholding."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the \"Funds\"), all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":8060},"source":{"system":"sec-edgar","filing":"0000899243-22-028860","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322028860/doc4.xml","form_type":"4"}},{"id":2183738,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124526,"kind":"person","name":"Royalty Pharma Investments 2019 ICAV","position":4,"cik":"0001909645","reported_name":"Royalty Pharma Investments 2019 ICAV","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.0001","published_at":"2022-08-16T22:55:40.000Z","date":"2022-08-12","kind":"other","acquired":false,"shares":31933334,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents (a) (i) 6,666,667 shares of the Issuer's common stock (\"Shares\") and (ii) 2,500,000 shares of the Issuer's common stock, in each case acquired by RPI Finance Trust (\"RPIFT\") pursuant to that certain Purchase Agreement, dated November 4, 2019, by and between the Issuer and RPIFT and (b) 22,666,667 shares of common stock acquired by Royalty Pharma Investments 2019 ICAV (\"RPI 2019 ICAV\") from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects disposition of Shares in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects disposition of Shares in connection with that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Ipsen Pharma SAS and Hibernia Merger Sub, Inc. (\"Merger Sub\"), dated as of June 27, 2022, including the completion of a tender offer to purchase all outstanding Shares of the Issuer, at a price per Share of (i) $1.45 per Share (the \"Cash Consideration\"), plus (ii) one (1) contractual contingent value right per Share (\"CVR\"), which represents the right to receive one or more contingent payments upon the achievement of certain milestones, if any (collectively, the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Merger Sub on August 12, 2022. As of the effective time of the Merger (the \"Effective Time\"), each Share held by the Reporting Person was converted into the Offer Price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"This Form 4 is being jointly filed by RP Management, LLC (\"RP Management\"), RPIFT, and Pablo G. Legorreta (collectively, the \"Reporting Persons\"). RP Management, as the manager of RPIFT and RPI 2019 ICAV, and Mr. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") of the securities beneficially owned by RPIFT and RPI 2019 ICAV. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta served on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Each of RPIFT, RPI 2019 ICAV and RP Management, LLC may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028860","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322028860/doc4.xml","form_type":"4"}},{"id":2208157,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Earnout Rights","published_at":"2022-07-13T21:30:22.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":10500000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units (\"Earnout RCUs\") and earnout restricted Class B Ordinary Shares (\"Earnout RSRs\" and together with the Earnout RCS, the \"Earnout Rights\") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons."},{"field":"shares","element":"transactionShares","label":"F7","text":"The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units (\"Earnout RCUs\") and earnout restricted Class B Ordinary Shares (\"Earnout RSRs\" and together with the Earnout RCS, the \"Earnout Rights\") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons."},{"field":"shares","element":"transactionShares","label":"F8","text":"One-third of the Earnout Rights will vest upon the volume weighted average price (\"VWAP\") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units (\"Earnout RCUs\") and earnout restricted Class B Ordinary Shares (\"Earnout RSRs\" and together with the Earnout RCS, the \"Earnout Rights\") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units (\"Earnout RCUs\") and earnout restricted Class B Ordinary Shares (\"Earnout RSRs\" and together with the Earnout RCS, the \"Earnout Rights\") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"The Earnout Rights were received pursuant to the terms of the Business Combination Agreement. Pursuant to the earnout provisions of the Business Combination Agreement, the reporting persons are entitled to receive earnout restricted Common Units (\"Earnout RCUs\") and earnout restricted Class B Ordinary Shares (\"Earnout RSRs\" and together with the Earnout RCS, the \"Earnout Rights\") that vest in three equal tranches based on the achievement of share price milestones set forth below in footnote (8) below. Once vested, the Earnout RCUs will automatically convert into Common Units and the Earnout RSRs will automatically convert into Class B Ordinary Shares, which, as noted in footnotes (3) and (5) above, may be exchanged for Class A Ordinary Shares at the election of the reporting persons."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F8","text":"One-third of the Earnout Rights will vest upon the volume weighted average price (\"VWAP\") of a Class A Ordinary Share reaching $15.00 per share for any 20 trading days over any consecutive 30 day trading period, an additional one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $20.00 per share for any 20 trading days over any consecutive 30 day trading period and the final one-third of the Earnout Rights will vest upon the VWAP of a Class A Ordinary Share reaching $25.00 per share for any 20 trading days over any consecutive 30 day trading period, in each case, such share price milestone must be achieved by the fifth anniversary of the Closing."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":10500000,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":10500000},"source":{"system":"sec-edgar","filing":"0000950103-22-012372","document":"dp177035_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095010322012372/dp177035_4-legorreta.xml","form_type":"4"}},{"id":2208156,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2022-07-13T21:30:22.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":94677968,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Common Unit may, at the election of the reporting persons and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"shares","element":"transactionShares","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"91,677,968 of the Common Units were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Common Units were acquired at the Closing pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment for a per unit price of $10. The Common Units do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":94677968,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":94677968},"source":{"system":"sec-edgar","filing":"0000950103-22-012372","document":"dp177035_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095010322012372/dp177035_4-legorreta.xml","form_type":"4"}},{"id":2208155,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78846,"kind":"organization","name":"Tolerantia, LLC","position":2,"cik":"0001937011","reported_name":"Tolerantia, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-07-13T21:30:22.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":94677968,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Does not include any Class B Ordinary Shares held by Control Empresarial de Capitales, S.A. de C.V. (\"CEC\") which executed a voting agreement pursuant to which through July 11, 2025, CEC will vote all Ordinary Shares beneficially held by it in a manner proportionate to the manner in which all other Class B Ordinary Shares not held by CEC (including those held by Tolerantia) are voted, solely with respect to the election, appointment or removal of any director to the issuer's board of directors."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022 (the \"Merger Proxy\")), be exchanged, together with the paired Common Unit in ProKidney LP (\"ProKidney\") (a \"Common Unit\"), for a Class A Ordinary Share on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F4","text":"91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the \"Closing\") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the \"Closing\") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the \"Closing\") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the \"Closing\") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"91,677,968 of the Class B Ordinary Shares were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting persons in ProKidney and 3,000,000 of the Class B Ordinary Shares were acquired at the closing of the transactions (the \"Closing\") contemplated by the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\"), pursuant to a subscription agreement between the reporting person and the issuer as part of the PIPE Investment (as defined in the Merger Proxy) for a per share price of $10. The Class B Ordinary Shares do not expire."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents equity interests held by Tolerantia, which is an affiliate controlled and majority owned by Pablo Legoretta. Mr. Legoretta controls the voting and disposition of the equity interests held by Tolerantia. Mr. Legorreta disclaims beneficial ownership of the equity interests held by Tolerantia except to the extent of his indirect pecuniary interest therein."}],"balance_after":94677968,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":94677968},"source":{"system":"sec-edgar","filing":"0000950103-22-012372","document":"dp177035_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1937011/000095010322012372/dp177035_4-legorreta.xml","form_type":"4"}},{"id":2263244,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124526,"kind":"person","name":"Royalty Pharma Investments 2019 ICAV","position":4,"cik":"0001909645","reported_name":"Royalty Pharma Investments 2019 ICAV","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-19T22:01:41.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":8994,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Consists of shares of common stock issuable under 8,994 RSUs granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director. Each RSU represents the right to receive one share of common stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Consists of shares of common stock issuable under 8,994 RSUs granted on May 17, 2022, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director. Each RSU represents the right to receive one share of common stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the \"Funds\"), all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":8994,"derivative":{"exercise_price":0,"exercise_date":"2023-05-17","underlying":"Common Stock","underlying_shares":8994},"source":{"system":"sec-edgar","filing":"0000899243-22-018914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322018914/doc4.xml","form_type":"4"}},{"id":2263243,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124526,"kind":"person","name":"Royalty Pharma Investments 2019 ICAV","position":4,"cik":"0001909645","reported_name":"Royalty Pharma Investments 2019 ICAV","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T22:01:41.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":41006,"price":0.56,"value":22963.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"This option was granted on May 17, 2022 with respect to 41,006 shares of common stock, and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director. In the event of a change in control of the Issuer, the option will vest in full."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by RPIFT, RPI 2019 ICAV, and certain of their respective indirect owners (such indirect owners, the \"Funds\"), all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV. Each of RPIFT, RPI 2019 ICAV and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":41006,"derivative":{"exercise_price":0.56,"exercise_date":"2023-05-17","expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":41006},"source":{"system":"sec-edgar","filing":"0000899243-22-018914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322018914/doc4.xml","form_type":"4"}},{"id":2296442,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2022-04-15T22:55:01.000Z","date":"2021-06-30","kind":"other","acquired":true,"shares":73332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F10","text":"Reflects the automatic transfer of ICAI Interests to the Reporting Person for no consideration upon the forfeiture of such ICAI Interests due to the retirement of an employee of RP Management, LLC."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Reflects the automatic transfer of ICAI Interests to the Reporting Person for no consideration upon the forfeiture of such ICAI Interests due to the retirement of an employee of RP Management, LLC."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":73332,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":73332},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296441,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2021-03-23","kind":"other","acquired":true,"shares":16012,"ownership":{"direct":false,"nature":"By Legorreta Investments II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Reflects the automatic transfers of RPI US LP Interests for no consideration from an employee of RP Management, LLC to Legorreta Investments LLC and Legorreta Investments II LLC in connection with a tax withholding event."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reflects the automatic transfers of RPI US LP Interests for no consideration from an employee of RP Management, LLC to Legorreta Investments LLC and Legorreta Investments II LLC in connection with a tax withholding event."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the exempt transfer pursuant to Rule 16a-13 of certain ICAI Interests, RPI US LP Interests and Class A Ordinary Shares from Legorreta Investments LLC to Legorreta Investments II LLC. As of the filing date, Legorreta Investments LLC has 811,759 ICAI Interests and 460,139 Class A Ordinary Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":2862363,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":160120},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296440,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2021-03-23","kind":"other","acquired":true,"shares":15947,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F8","text":"Reflects the automatic transfers of RPI US LP Interests for no consideration from an employee of RP Management, LLC to Legorreta Investments LLC and Legorreta Investments II LLC in connection with a tax withholding event."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Reflects the automatic transfers of RPI US LP Interests for no consideration from an employee of RP Management, LLC to Legorreta Investments LLC and Legorreta Investments II LLC in connection with a tax withholding event."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the exempt transfer pursuant to Rule 16a-13 of certain ICAI Interests, RPI US LP Interests and Class A Ordinary Shares from Legorreta Investments LLC to Legorreta Investments II LLC. As of the filing date, Legorreta Investments LLC has 811,759 ICAI Interests and 460,139 Class A Ordinary Shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F9","text":"Reflects the forfeiture of 67,227 RPI US LP Interests without the payment of any consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":2850640,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":159470},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296439,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":5748271,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":428420},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296438,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":5791113,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":428420},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296437,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2022-04-15T22:55:01.000Z","date":"2020-10-20","kind":"exercise","acquired":false,"shares":42842,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":1626857,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":42842},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296436,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":49375,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":5748271,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":493750},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296435,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2022-04-15T22:55:01.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":49375,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"The Reporting Person has agreed to retain and not sell 5,103,392 RPI US LP Interests convertible into 51,033,928 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances."}],"balance_after":5797646,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":493750},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296434,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2022-04-15T22:55:01.000Z","date":"2020-06-16","kind":"exercise","acquired":false,"shares":49375,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These ICAI Interests represent a grant of up to an equivalent number of RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F7","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":1669699,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":49375},"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296433,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2022-04-15T22:55:01.000Z","date":"2022-04-14","kind":"other","acquired":false,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents the transfer by the Reporting Person of Class A ordinary shares for no consideration to RP Management Equity Incentive Plan Trust."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Reflects shares received in exempt pro rata distribution pursuant to Rule 16a-9(a) from Legorreta Investments II LLC, 413,795 Class A ordinary shares to the Reporting Person directly, 6,930 Class A ordinary shares to the Reporting Person's spouse and 41,306 Class A ordinary shares to the GST-Exempt 2020 Family Trust."}],"balance_after":63795,"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296432,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2022-04-15T22:55:01.000Z","date":"2022-04-14","kind":"other","acquired":false,"shares":462031,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments II LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Reflects the pro rata distribution from Legorreta Investments II LLC to their respective members for no consideration."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects the exempt transfer pursuant to Rule 16a-13 of certain ICAI Interests, RPI US LP Interests and Class A Ordinary Shares from Legorreta Investments LLC to Legorreta Investments II LLC. As of the filing date, Legorreta Investments LLC has 811,759 ICAI Interests and 460,139 Class A Ordinary Shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296431,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2022-04-15T22:55:01.000Z","date":"2020-10-20","kind":"exercise","acquired":true,"shares":428420,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."}],"balance_after":922170,"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296430,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2022-04-15T22:55:01.000Z","date":"2020-06-16","kind":"exercise","acquired":true,"shares":493750,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"), which were themselves received upon conversion of ICAI Interests. Each ICAI Interest was exchanged for limited partnership interest in RPI US LP (\"RPI US LP Interest\") on a one-for-one basis. Each RPI US LP Interest was then exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with these exchanges."}],"balance_after":493750,"source":{"system":"sec-edgar","filing":"0000950103-22-006475","document":"dp171092_4-legoretta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006475/dp171092_4-legoretta.xml","form_type":"4"}},{"id":2296429,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2022-04-15T22:49:05.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":1719074,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\") and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI International Holdings 2019, LP (\"RPI Intl. LP\") for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These ICAI Interests represent a grant of up to 1,719,074 RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These ICAI Interests represent a grant of up to 1,719,074 RPI US LP Interests and expire on December 15, 2023. The full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This amendment to Form 4 is being filed to correct the terms and the number of ICAI Interests that was incorrectly reported on the Reporting Person's original Form 4 due to an inadvertent administrative error."}],"balance_after":1719074,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":1719074},"source":{"system":"sec-edgar","filing":"0000950103-22-006474","document":"dp171118_4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010322006474/dp171118_4a.xml","form_type":"4/A","original_submission_date":"2020-06-22"}},{"id":2418887,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-01T21:17:51.000Z","date":"2022-01-31","kind":"purchase","acquired":true,"shares":22666667,"price":1.5,"value":34000000.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents (a) (i) 6,666,667 shares of the Issuer's common stock and (ii) 2,500,000 shares of the Issuer's common stock, in each case acquired by RPI Finance Trust (\"RPIFT\") pursuant to that certain Purchase Agreement, dated November 4, 2019, by and between the Issuer and RPIFT and (b) 22,666,667 shares of common stock acquired by Royalty Pharma Investments 2019 ICAV (\"RPI 2019 ICAV\") from the underwriter in an underwritten public offering conducted by the Issuer that closed on January 31, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being jointly filed by RP Management, LLC (\"RP Management\"), RPIFT, and Pablo G. Legorreta (collectively, the \"Reporting Persons\"). RP Management, as the manager of RPIFT and RPI 2019 ICAV, and Mr. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") of the securities beneficially owned by RPIFT and RPI 2019 ICAV. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT and RPI 2019 ICAV."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of RPIFT, RPI 2019 ICAV and RP Management, LLC may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":31833334,"source":{"system":"sec-edgar","filing":"0000899243-22-003857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924322003857/doc4.xml","form_type":"4"}},{"id":2667770,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-15T21:14:01.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":8060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Consists of shares of common stock issuable under 8,060 restricted stock units (\"RSUs\") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director. Each RSU represents the right to receive one share of common stock upon vesting.  In the event of a change in control of the Issuer, the RSUs will vest in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Consists of shares of common stock issuable under 8,060 restricted stock units (\"RSUs\") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director. Each RSU represents the right to receive one share of common stock upon vesting.  In the event of a change in control of the Issuer, the RSUs will vest in full."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by certain indirect owners (the \"Funds\") of RPIFT, all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT. Each of RPIFT and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":8060,"derivative":{"exercise_price":0,"exercise_date":"2022-06-11","underlying":"Common Stock","underlying_shares":8060},"source":{"system":"sec-edgar","filing":"0000899243-21-023897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924321023897/doc4.xml","form_type":"4"}},{"id":2667769,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T21:14:01.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":40559,"price":8.53,"value":345968.27,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on June 11, 2021 with respect to 40,559 shares of common stock, and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to Mr. Legorreta's continued service as a director.  In the event of a change in control of the Issuer, the option will vest in full."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the derivative security and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the derivative security, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the derivative security will be offset against the management fee payable to RP Management by certain indirect owners (the \"Funds\") of RPIFT, all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 5) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT. Each of RPIFT and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":40559,"derivative":{"exercise_price":8.53,"exercise_date":"2022-06-11","expiration_date":"2031-06-11","underlying":"Common Stock","underlying_shares":40559},"source":{"system":"sec-edgar","filing":"0000899243-21-023897","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924321023897/doc4.xml","form_type":"4"}},{"id":2718828,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-05-12T01:03:39.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":128459,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GST-Exempt Legorreta 2012 Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1284590},"source":{"system":"sec-edgar","filing":"0000950103-21-007075","document":"dp150861_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007075/dp150861_4-legorreta.xml","form_type":"4"}},{"id":2718827,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2021-05-12T01:03:39.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":104041,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Children 2002 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1040410},"source":{"system":"sec-edgar","filing":"0000950103-21-007075","document":"dp150861_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007075/dp150861_4-legorreta.xml","form_type":"4"}},{"id":2718826,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2021-05-12T01:03:39.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":1284590,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GST-Exempt Legorreta 2012 Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":1284590,"source":{"system":"sec-edgar","filing":"0000950103-21-007075","document":"dp150861_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007075/dp150861_4-legorreta.xml","form_type":"4"}},{"id":2718825,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2021-05-12T01:03:39.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":1040410,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Children 2002 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP\"). Each limited partnership interest in RPI US LP (\"RPI US LP Interest\") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited (\"Holdings\"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value will be paid by the Reporting Person in connection with the exchange."}],"balance_after":1040410,"source":{"system":"sec-edgar","filing":"0000950103-21-007075","document":"dp150861_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010321007075/dp150861_4-legorreta.xml","form_type":"4"}},{"id":3103263,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":11850,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SEP/ IRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"Includes RPI Intl. LP Interests convertible into 9,240 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":924,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":118500},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103262,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"exercise","acquired":false,"shares":12331,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRRA"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes RPI Intl. LP Interests convertible into 9,620 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":962,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":123310},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103261,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"ICAI Interests","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":1677574,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"These ICAI Interests represent a grant of up to 1,677,574 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"These ICAI Interests represent a grant of up to 1,677,574 RPI US LP Interests. These ICAI Interests expire on December 15, 2023, and are subject to four-year vesting, with 25% of the interests vesting on February 12, 2021 and the remainder vesting in 36 equal monthly installments thereafter. Subject to these vesting requirements, the full number of RPI US LP Interests is issuable in respect of these ICAI Interests if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The number of RPI US LP Interests issuable in respect of these ICAI Interests scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."}],"balance_after":1677574,"derivative":{"exercise_price":0,"underlying":"Limited Partnership interests in RPI US Partners 2019, LP","underlying_shares":1677574},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103260,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":12774,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SEP/IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F11","text":"Includes RPI Intl. LP Interests convertible into 9,240 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":12774,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":127740},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103259,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI International Holdings 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":13293,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Represents limited partnership interests in RPI Intl. LP Interests. Each RPI Intl. LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI Intl. LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F10","text":"Includes RPI Intl. LP Interests convertible into 9,620 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":13293,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":132930},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103258,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":4868033,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Includes RPI US LP Interests convertible into 37,432,416 Class A Ordinary Shares that are subject to an agreement by and between the reporting person and RP Management, LLC under which the reporting person has agreed to retain and not sell such interests before February 2025. This restriction is waivable under certain circumstances."}],"balance_after":4868033,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":48680330},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103257,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":138479,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By GST-Exempt Legorreta 2012 Family Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"Includes RPI US LP Interests convertible into 100,200 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":138479,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1384790},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103256,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":112156,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Children 2002 Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Includes RPI US LP Interests convertible into 81,150 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":112156,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":1121560},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103255,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"LP interests in RPI US Partners 2019, LP","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-15","kind":"grant","acquired":true,"shares":942738,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Legorreta Investments LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The Reporting Person acquired beneficial ownership of Class B Interests in Holdings and became entitled to indirect rights to exchange such Class B Interests for Class A Ordinary Shares of the Issuer in connection with a reorganization prior to closing of the Issuer's initial public offering (as more fully described in the Issuer's Registration Statement on Form S-1 (File No. 333-238632)). The reorganization involved the exchange of interests in Royalty Pharma Investments 2019 ICAV held by RPI US Partners 2019, LP (\"RPI US LP\") and RPI Intl. LP for interests in Holdings. The reorganization and the acquisition of these exchange rights occurred on June 15, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents limited partnership interests in RPI US Partners 2019, LP (\"RPI US LP Interests\"). Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged upon such exchange for one Class A Ordinary Share of the Issuer for no additional value."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes RPI US LP Interests convertible into 672,270 Class A Ordinary Shares that are subject to forfeiture if and when the Class A Ordinary Shares attain a 20-trading day volume weighted average price of $32.30 or more after December 15, 2020 and on or before December 15, 2023. The amount of this forfeiture scales linearly from 0% at $20.51 per share to 100% at $32.30 per share."}],"balance_after":942738,"derivative":{"exercise_price":0,"underlying":"Class A Ordinary Shares","underlying_shares":9427380},"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103254,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":118500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By SEP/IRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":118500,"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103253,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":123310,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By IRRA"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This exchange was effected by the General Partner of RPI Intl. LP in accordance with a provision of the Limited Partnership Agreement of RPI Intl. LP applicable in the event of the public offering of the Issuer's Class A Ordinary Shares. The exchange applied to all holders of RPI Intl. LP Interests that did not opt out of participation."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These Class A Ordinary Shares were received by the Reporting Person in exchange for limited partnership interests in RPI International Holdings 2019, LP (\"RPI Intl. LP\"). Each limited partnership interest in RPI Intl. LP (\"RPI Intl. LP Interest\") was exchanged for ten Class B Interests in Royalty Pharma Holdings Ltd, (\"Holdings\"). Each Class B Interest in Holdings so distributed was exchanged for one Class A Ordinary Share of the Issuer. This exchange was made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Company, Royalty Pharma Holdings Limited, RPI US Partners 2019, LP, RPI Intl. LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the \"Exchange Agreement\"). No additional value was paid by the Reporting Person in connection with the exchange."}],"balance_after":123310,"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103252,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"purchase","acquired":true,"shares":10000,"price":28,"value":280000.0,"ownership":{"direct":false,"nature":"By Child"},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3103251,"issuer":{"id":3100,"kind":"organization","name":"Royalty Pharma plc","symbol":"RPRX"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, Chairman of the Board"}}],"security":"Class A Ordinary Shares","published_at":"2020-06-23T01:55:45.000Z","date":"2020-06-18","kind":"purchase","acquired":true,"shares":10000,"price":28,"value":280000.0,"ownership":{"direct":false,"nature":"By Child"},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000950103-20-012150","document":"dp130796_4-legorreta.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1802768/000095010320012150/dp130796_4-legorreta.xml","form_type":"4"}},{"id":3126533,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-02T20:23:09.000Z","date":"2020-05-29","kind":"grant","acquired":true,"shares":14103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option will vest in full on May 29, 2021, subject to Mr. Legorreta's continued service as a director.  In the event of a change in control of the Issuer, the option will become exercisable in full."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Mr. Legorreta is deemed to hold the stock option and the shares issuable thereunder for the benefit of RP Management. Mr. Legorreta is the manager of RP Management. Any exercise of the stock option, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the stock option will be offset against the management fee payable to RP Management by certain indirect owners (the \"Funds\") of RPIFT, all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"(Continued from Footnote 6) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT. Each of RPIFT and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":14103,"derivative":{"exercise_price":17.55,"exercise_date":"2021-05-29","expiration_date":"2029-05-29","underlying":"Common Stock","underlying_shares":14103},"source":{"system":"sec-edgar","filing":"0000899243-20-014907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924320014907/doc4.xml","form_type":"4"}},{"id":3273501,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":104117,"kind":"organization","name":"RP Management, LLC","position":2,"cik":"0001507673","reported_name":"RP Management, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":124525,"kind":"person","name":"RPI Finance Trust","position":3,"cik":"0001793690","reported_name":"RPI Finance Trust","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-13T23:47:04.000Z","date":"2020-02-11","kind":"grant","acquired":true,"shares":2500000,"price":20,"value":50000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents 2,500,000 shares of the Issuer's common stock acquired by RPI Finance Trust (\"RPIFT\") on February 11, 2020 pursuant to that certain Purchase Agreement, dated November 4, 2019, by and between the Issuer and RPIFT (the \"Purchase Agreement\"), whereby the Issuer had the option, subject to certain conditions, to sell $50 million of its common stock to RPIFT until May 6, 2021 at a maximum price of $20.00 per share. The Issuer exercised this option on December 30, 2019 and on February 11, 2020, the Issuer issued and sold to RPIFT 2,500,000 shares of its common stock at a price of $20.00 per share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being jointly filed by RP Management, LLC (\"RP Management\"), RPIFT and Pablo G. Legorreta (collectively, the \"Reporting Persons\"). RP Management, as the manager of RPIFT, and Mr. Legorreta, as the manager of RP Management, may be deemed to have beneficial ownership under Section 13 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\") of the securities beneficially owned by RPIFT. RP Management and Mr. Legorreta disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that RP Management and/or Mr. Legorreta are the beneficial owners thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Each of RPIFT and RP Management, LLC may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":9166667,"source":{"system":"sec-edgar","filing":"0000899243-20-004530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924320004530/doc4.xml","form_type":"4"}},{"id":3376158,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":25466,"kind":"person","name":"Legorreta Pablo G.","position":1,"cik":"0001507678","reported_name":"Legorreta Pablo G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-09T00:10:40.000Z","date":"2019-11-06","kind":"grant","acquired":true,"shares":34408,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted to Mr. Legorreta on November 6, 2019 pursuant to the Issuer's 2013 Stock Incentive Plan with respect to 34,408 shares of Common Stock, in connection with Mr. Legorreta's election to the board of directors of the Issuer. This option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 2.0833% of the shares at the end of each successive month following the first anniversary of the grant date until the fourth anniversary of the grant date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Mr. Legorreta is deemed to hold the stock option and the shares issuable thereunder for the benefit of RP Management, LLC (\"RP Management\"). Mr. Legorreta is the manager of RP Management. Any exercise of the stock option, when vested, or sale of the shares issuable upon exercise shall be at the direction of RP Management and the proceeds of the sale of the shares issuable upon exercise shall be delivered to RP Management. The proceeds of the sale of the shares issuable under the stock option will be offset against the management fee payable to RP Management by certain indirect owners (the \"Funds\") of RPI Finance Trust (\"RPIFT\"), all of which are managed by RP Management."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"(Continued from Footnote 2) Mr. Legorreta and such Funds disclaim beneficial ownership of the securities indicated except to the extent of their pecuniary interest therein, and the reporting herein of such securities shall not be construed as an admission that Mr. Legorreta or any of such Funds is the beneficial owner thereof for purposes of Section 16 of the Exchange Act or for any other purpose. Mr. Legorreta serves on the board of directors of the Issuer as a representative of RPIFT. Each of RPIFT and RP Management may be deemed to be a director by deputization of the Issuer for purposes of Section 16(b)-3(d) of the Exchange Act."}],"balance_after":34408,"derivative":{"exercise_price":13.51,"expiration_date":"2029-11-05","underlying":"Common Stock","underlying_shares":34408},"source":{"system":"sec-edgar","filing":"0000899243-19-027026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1507678/000089924319027026/doc4.xml","form_type":"4"}}]}